A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

NCT01369355 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1282

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease
Colitis
IBD
Inflammatory Bowel Disease

Interventions

DRUG: Placebo SC
DRUG: Placebo IV
DRUG: Ustekinumab 90 mg SC q8w
DRUG: Ustekinumab 130 mg IV
DRUG: Ustekinumab 90 mg SC q12w

Sponsor

Janssen Research & Development, LLC